Health Secretary Wes Streeting will be meeting victims of the 'silent scandal' involving diethylstilbestrol (DES), a synthetic estrogen that was prescribed to pregnant women from the 1940s through the 1970s. This drug has been linked to serious health issues, including various types of cancer and reproductive problems for those who were exposed. Family members of affected individuals, including children and grandchildren, have experienced life-altering consequences due to their exposure to the drug.

The meeting aims to address the long-standing grievances of those impacted by this scandal, which has often gone unnoticed in public discussions about pharmaceutical safety. One notable victim, Susie Martin from Manchester, shared the profound effects the drug has had on her life, stating that she has undergone numerous surgeries as a direct result of the complications stemming from her mother's use of DES. Her story highlights the significant medical and emotional toll on families affected by the drug.

Health Secretary Streeting's engagement with the victims represents an important step towards acknowledging these harms and potentially creating changes to support those affected. This meeting comes amid growing calls for accountability from pharmaceutical companies and the need for better regulations to prevent similar incidents in the future. The response from the government and health authorities will be closely watched by both victims and advocates for change in drug safety oversight.